


# Leveraging Novel **ANTIBODY-DRUG CONJUGATES** in a World of Evolving Treatment Paradigms: A **PAN-TUMOR** Perspective



**Saturday, November 21, 2020**

12:00 - 13:30 SGT

Channel 7



## Benefits of Attending:

- Learn about potential new applications for antibody-drug conjugates (ADCs) in solid tumors
- Hear expert perspectives on managing adverse events associated with ADC therapy
- Integrate cutting-edge therapies for your patients with breast, lung, or GI tumors
- Participate in discussions with expert faculty through a custom, interactive platform

## Agenda Highlights:

- Rationale for Novel Antibody-Drug Conjugate Treatment: A Focus on HER2/3 and Unmet Needs in Testing
- The Advent of Novel HER2/3 Approaches in Breast Cancer Care: Recent Evidence in the Context Evolving Treatment Paradigms
- HER2/3 Antibody-Drug Conjugate Treatment Strategies Across GI Malignancies: Where Are We and Where Are We Going?
- Emerging Novel Antibody-Drug Conjugate Treatment Strategies in Lung Cancer

## Program Chair:



### **Masakazu Toi, MD, PhD**

Breast Cancer Unit, Kyoto  
University Hospital  
Professor of Breast Surgery,  
Graduate School of Medicine  
Kyoto University  
Kyoto, Japan

### Accreditation/Credit Designation

Physicians' Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### Acknowledgment of Commercial Support

This activity is supported by an educational grant from Daiichi Sankyo.